

BEST OF SABCS CROATIA, Zagreb 20. - 21. February 2026.

PROGRAMME

FRIDAY, 20.2.2026.

14:30 Welcome and Introductions

14:40-15:50 Section 1.

Moderator Martina Bašić Koretić

- Z. MARUŠIĆ** Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stageII/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181/CompassHER2 pCR trial
- M. JAZVIĆ** Prognostic Markers in Residual Tumors after Neoadjuvant Chemotherapy (NACT) fo Early Triple-Negative Breast Cancer (TNBC)– a Pooled Analysis from nine Neoadjuvant GBG/AGO-B trials
- S. PLEŠTINA** Effect of Adjuvant Carboplatin Intensified Chemotherapy versus StandardChemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE): A Phase 3 Randomized Trial .
- J. FLAM** Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
- T. SILOVSKI** Sacituzumab Govitecan vs Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2– (IHC 0, 1+, 2+/ISH–) Metastatic Breast Cancer: Primary Results From ASCENT-07

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

15:50-16:20 Satellite Symposium: Eli Lilly

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

16:20-16:50 Satellite Symposium: Novartis

16:50-17:20 Coffee break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

17:20-17:50 Satellite Symposium: Roche

17:50-18:50 Section 2.

Moderator Marijana Jazvić

A. STRIKIĆ Efficacy Analysis of the Randomized Phase III DETECT Trial: Treatment De- escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2 positive and Hormone Positive Metastatic Breast Cancer

M. BAN Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

- J. CORTES** Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial.
- N. ŠARIĆ** Optimizing De-escalation in Low-Risk HR+ Early-Stage Breast Cancer Radiation therapy or endocrine therapy: Which one to omit

18:50 End of program

SATURDAY, 21.2.2026.

9:00-10:00 Section 3.

Moderator Željko Soldić

- S. TOMIĆ** HER2 low/ultralow: what the pathologist sees
- B. PETRIĆ MIŠE** DESTINY-Breast11 safety: neoadjuvant trastuzumab deruxtecan(T-DXd) alone or followed by paclitaxel + trastuzumab +pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer
- A. BUDISAVLJEVIĆ** Trastuzumab deruxtecan vs trastuzumab emtansine in pts with high risk HER2+ primary breast cancer with residual disease after neoadj th: interim analysis of Destiny -Breast 05.
- N. DEDIĆ PLAVETIĆ** HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer
- M. PRUTKI** Effect of preoperative breast MRI Staging on Local regional recurrence (LRR) in early stage Breast Cancer: ALLiance AO11104/ACRIN6694

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:00-10:30 Satellite Symposium Novartis

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

10:30-11:00 Satellite Symposium Eli Lilly

11:00-11:20 Coffee break

11:20-12:35 Section 4.

Moderator Sanda Smuđ Orehovec

I. MILAS Omission of sentinel lymph node biopsy in clinically T1-2N0 breast cancer patients treated with breast- conserving therapy: results of the Dutch BOOG2013-08 randomized controlled after a median follow-up of 5 years

A. DUJMOVIĆ More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy-primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R) study

K. ANTUNAC Advances in breast radiotherapy: Less is more!

M. SOČE Should we irradiate the IM Nodes: Settling the Issue

T. MLINARIĆ KOPRIVANAC

Repeat breast conservation with re-irradiation: What is the data and how do we do it

The satellite symposium section is not a part of the official program
of the Best of SABCS.

12:35-12:55

Satellite Symposium: Pfizer

13:00-14:00 Lunch/Break

The satellite symposium section is not a part of the official program
of the Best of SABCS.

14:00 – 14:45

Satellite Symposium Astra Zeneca

14:45-15:35 Section 5.

Moderator Ingrid Belac Lovasić

I. BIONDIĆ

Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

D. HUIĆ FDG-PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE ECOG-ACRIN EA1183

P. SERTIĆ Cardiotoxicity of breast cancer novel therapies

J. JOVIĆ ZLATOVIĆ
Impact of Immune Checkpoint Inhibition on Fertility in Young Women with Early Triple-Negative Breast Cancer receiving neoadjuvant Chemotherapy: A prospective Substudy of the NSABP B-59/GeparDouzeTrial

15:35-16:25 CLINICAL CONTROVERSIES:

Management of the Axilla in Multidisciplinary Care

R. ŽIĆ De-escalation of axillary surgery after NAC in clinically node positive patients

K. ANTUNAC De-Escalation of Regional Nodal Irradiation after NAC in Clinically Node Positive Patients

16:25-16:45 Coffee break

16:45-17:25 Section 6. YEAR IN THE REVIEW

Moderator Eduard Vrdoljak

M. BAŠIĆ KORETIĆ Early breast cancer

E. VRDOLJAK Advanced breast cancer

17:25-17:40 WHAT WILL WE DO ON MONDAY MORNING?

17:40 Summary and Closing Remarks

17:45 End of the Symposium

